2.45

6.84% -0.18

Alaunos Therapeutics Inc (TCRT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Alaunos Therapeutics Inc stock is traded at $2.45, with a volume of 63,356. It is down -6.84% in the last 24 hours and up +67.81% over the past month. Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.

Previous Close:

$2.63

Open:

$2.69

24h Volume:

63,356

Relative Volume:

0.14

Market Cap:

$3.76M

Revenue:

Net Income/Loss:

$-36.46M

P/E Ratio:

-1.0208

EPS:

-2.4

Net Cash Flow:

$-30.20M

1W Performance:

+4.26%

1M Performance:

+67.81%

6M Performance:

+19.00%

1Y Performance:

-81.44%

1-Day Range:

$2.32

$2.8588

1-Week Range:

$2.2704

$2.86

52-Week Range:

$1.3137

$14.20

Alaunos Therapeutics Inc Stock (TCRT) Company Profile

Name

Alaunos Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (673)

Phone

(346) 355-4099

Address

2617 BISSONNET ST, HOUSTON

Employee

Twitter

Next Earnings Date

2024-12-12

Latest SEC Filings

TCRT's Discussions on Twitter

Compare TCRT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TCRT Alaunos Therapeutics Inc	2.45	3.76M	0	-36.46M	-30.20M	-2.40
VRTX Vertex Pharmaceuticals Inc	496.49	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.86	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	620.97	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	254.85	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.46	24.70B	3.81B	-644.79M	-669.77M	-6.24

Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-04-22	Resumed	Wells Fargo	Overweight

Alaunos Therapeutics Inc Stock (TCRT) Latest News

Apr 24, 2025

Alaunos Therapeutics (NASDAQ:TCRT) Trading Up 2.5% – Time to Buy? - Defense World

Apr 24, 2025

Apr 18, 2025

Alaunos Therapeutics announces board member resignation - Investing.com Australia

Apr 18, 2025

Alaunos Therapeutics announces board member resignation By Investing.com - Investing.com Canada

Apr 18, 2025

Apr 16, 2025

Form 8-KCurrent report - ADVFN

Apr 16, 2025

Apr 15, 2025

Alaunos Therapeutics Board Opts for Equity Compensation - TipRanks

Apr 15, 2025

Apr 14, 2025

Alaunos Therapeutics announces private placement of preferred stock By Investing.com - Investing.com Canada

Apr 14, 2025

Alaunos Therapeutics announces private placement of preferred stock - Investing.com

Apr 14, 2025

Apr 04, 2025

Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st

Apr 04, 2025

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World

Apr 04, 2025

Apr 03, 2025

Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World

Mar 27, 2025

Jan 29, 2025

Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology

Jan 29, 2025

Jan 15, 2025

Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World

Jan 15, 2025

Jan 13, 2025

Update: Johnson & Johnson acquires Intra-Cellular Therapies - Pharmaceutical Technology

Jan 13, 2025

Jan 10, 2025

Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology

Jan 10, 2025

Dec 24, 2024

Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World

Dec 24, 2024

Dec 13, 2024

TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com

Dec 13, 2024

Nov 22, 2024

Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology

Nov 22, 2024

Nov 15, 2024